Last 24 quarters of trend data · Healthcare · Neuroscience Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 | Q4 '19 | Q2 '19 | Q4 '18 | Q2 '18 | Q4 '17 | Q2 '17 | Q4 '16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -4.30 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 1565.45 | — | 3386.36 | 20.06 | 18.87 | 51.08 | 10.37 | 5.23 | 3.11 | 3.75 | 2.83 | 3.62 | 2.69 | 31.34 | — | — | 489.99 | — | — | — | — |
| — | — | +32569.3% | +283.6% | +506.2% | +1260.9% | +266.8% | +44.5% | +15.7% | -88.0% | — | — | -99.5% | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | 77.68 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 | Q4 '19 | Q2 '19 | Q4 '18 | Q2 '18 | Q4 '17 | Q2 '17 | Q4 '16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 | Q4 '19 | Q2 '19 | Q4 '18 | Q2 '18 | Q4 '17 | Q2 '17 | Q4 '16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -924.3% | — | -276.7% | -85.7% | -249.0% | -125.9% | -96.4% | -52.4% | -55.6% | -14.9% | -7.1% | -37.0% | -82.6% | -500.5% | — | — | -893.1% | — | — | -200.7% | -62.8% |
| — | — | -187.1% | -63.5% | -347.7% | -747.6% | -1250.9% | -41.7% | +32.7% | +97.0% | — | — | +90.7% | — | — | — | -1322.8% | — | — | -89.4% | +43.3% | |
| ROA | -161.8% | -107.0% | -91.1% | -40.4% | -64.8% | -40.2% | -61.3% | -39.3% | -41.1% | -12.0% | -6.0% | -27.2% | -51.2% | -66.6% | -239.8% | -102.8% | -107.2% | -232.7% | -150.4% | -91.4% | -50.4% |
| — | -166.1% | -48.6% | -2.9% | -57.6% | -234.9% | -918.9% | -44.4% | +19.7% | +82.0% | +97.5% | +73.6% | +52.2% | +71.4% | -59.5% | -12.5% | -112.7% | -469.2% | -210.9% | -1.5% | +9.6% | |
| ROIC | — | — | — | -580.4% | -1140.0% | -177.3% | -119.6% | -147.1% | -416.5% | -743.7% | — | — | — | — | — | — | — | — | -56.1% | -57.3% | — |
| — | — | — | -294.6% | -173.7% | +76.2% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 | Q4 '19 | Q2 '19 | Q4 '18 | Q2 '18 | Q4 '17 | Q2 '17 | Q4 '16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 8.77 | — | 8.77 | 0.01 | 0.03 | 0.10 | 0.04 | 0.03 | 0.02 | 0.02 | — | 0.02 | 0.01 | 0.18 | — | — | 0.60 | — | — | 235.55 | 0.07 |
| — | — | +19554.5% | -56.2% | +44.4% | +417.4% | — | +12.8% | +53.6% | -89.6% | — | — | -98.0% | — | — | — | +779.8% | — | — | +711015.0% | -41.4% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 0.76 | 0.69 | 0.76 | 1.72 | 1.02 | 0.85 | 1.12 | 3.85 | 3.64 | 3.64 | 6.45 | 6.54 | 8.79 | 1.86 | 0.15 | 0.25 | 1.08 | 0.31 | 0.52 | 1.02 | 2.89 |
| — | -18.7% | -32.0% | -55.4% | -72.0% | -76.6% | -82.6% | -41.1% | -58.6% | +96.4% | +4066.1% | +2529.5% | +714.3% | +489.1% | -70.0% | -75.6% | -62.7% | -96.6% | -95.8% | -89.2% | -19.7% | |
| Quick Ratio | 0.76 | 0.69 | 0.76 | 1.72 | 1.02 | 0.85 | 1.12 | 3.85 | 3.64 | 3.64 | 6.45 | 6.54 | 8.79 | 1.86 | 0.15 | 0.25 | 1.08 | 0.31 | 0.52 | 1.02 | 2.89 |
| — | -18.7% | -32.0% | -55.4% | -72.0% | -76.6% | -82.6% | -41.1% | -58.6% | +96.4% | +4066.1% | +2529.5% | +714.3% | +489.1% | -70.0% | -75.6% | -62.7% | -96.6% | -95.8% | -89.2% | -19.7% | |
| Interest Coverage | -1022.94 | — | — | — | -1460.00 | — | -1724.00 | -1722.40 | -1553.86 | — | — | -848.79 | -79.66 | -811.44 | -58.20 | -761.57 | -760.56 | -934.36 | -788.16 | -1060.17 | -916.22 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 24 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TLSA stock.
Tiziana Life Sciences Ltd's current P/E is -4.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Tiziana Life Sciences Ltd's business trajectory between earnings reports.